Haoyu (6872) “Focused Ultrasound” epilepsy treatment animal test results published in international journals
The team of Professor Liu Haoli, the founder of Haoyu Biomedical (6872), an innovative medical materials research and development company, used focused ultrasound to treat the hippocampus of the epileptic rat brain non-invasively, which can prevent epileptic damage and protect the nerves. It was published in the latest issue of the international journal “Neurology Therapeutics (Neurotherapeutics)”. Nowadays, most epilepsy patients have lesions in the hippocampus, accompanied by various mental complications, and even unable to take care of themselves and need the care of their family members. They suffer from the discomfort of seizures and the risk of accidents, which are long-term mental and economic troubles for individuals and families.
In a previous phase I/II study report, a single administration of focused ultrasound showed the potential to reduce seizure frequency. This latest study is the first time that “multiple administration” of focused ultrasound therapy was used to observe the improvement of bad behavior in chronic epileptic mice, and for the first time using nuclear magnetic resonance (MRI) images to confirm that focused ultrasound therapy can prevent epileptic mice from The brain lesions and tissue atrophy of the brain; and through the observation of pathological sections, it was found that the inflammation of the hippocampus was reduced, showing that ultrasound therapy has a neuroprotective effect. At the same time, the behavioral disorders such as anxiety and cowering, limb movement impairment, impaired memory and learning ability, and reduced social willingness in the epileptic mice, after the “multiple administration” treatment of focused ultrasound, increased their interest in outward exploration ( Anxiety decreased), physical incoordination improved, memory and learning ability recovered, social interaction increased, and the overall condition improved.
Haoyu Biomedical (6872) is conducting a phase II clinical trial of refractory epilepsy (DRE) in Beirong. The experimental design of “multiple administration” of focused ultrasonic energy echoes the team’s published research results. The trial will assess similar overt behavioral indicators such as whether the number or interval of patients’ seizures is slowing down? Has behavioral function improved? The effectiveness of relevant clinical treatments is expected to be published at the International Epilepsy Annual Meeting in September this year.
About 6.5 million people in the world suffer from epilepsy. The main treatment is drug control, but about 30% of the patients are drug-resistant epilepsy (DRE). According to the definition of the International League Against Epilepsy (ILAE), DRE refers to the situation that the use of two properly selected and used antiepileptic drugs (AED) treatment still cannot achieve continuous non-seizure; currently DRE can only rely on invasive treatment, including Surgical resection, radiofrequency ablation (RFA), deep brain shock (DBS), vagus nerve stimulation (VNS), and stereotaxic radiosurgery (SRS). The above-mentioned invasive methods have many disadvantages of high side effects, patient rejection, or uncertain prognosis. Therefore, the non-invasive treatment plan of “low-energy non-invasive transcranial focused ultrasound” can be safer and can accurately target deep lesions ( Such as the hippocampus) for treatment to improve the treatment effect.
The National Taiwan University team that Professor Liu participated in recently competed fiercely with the Hong Kong University of Science and Technology and the University of Singapore. With its abundant research and development energy and international visibility, it won the 2024 annual meeting of the International Symposium of Therapeutic Ultrasound (ISTU) Hosted in Taipei. The symposium is the most important event in the field of therapeutic ultrasound in the world, and the participants of the symposium are all elites focusing on the field of ultrasound technology. Haoyu Biomedical (6872), with the aura of the Edison Gold Award in 2022, will announce the progress of the above-mentioned experiments at the venue next year, and further demonstrate “low-energy non-invasive cranial transcranial focused ultrasound therapy to international scholars and manufacturers in the ultrasound medical field ”’s international leading position, and then jointly promote its commercial value, launch it on the market as soon as possible, and benefit patients.
